Vyvanse vs Adderall

The prodrug mechanism

Lisdexamfetamine is dextroamphetamine covalently bonded to L-lysine. In its bonded form the molecule does not bind to monoamine transporters and produces no stimulant effect — it is pharmacologically inert until activated. Pennick 2010¹ worked out the activation step: red-cell peptidases cleave the lysine bond as the molecule transits the bloodstream, releasing free d-amphetamine at a rate the enzyme capacity caps. The lysine is acting as a flow regulator built into the molecule.

Three consequences fall out of that mechanism. The plasma curve is slow-rising — peak at roughly 3.5 hours, with no rush, because the cleavage rate caps the input rate. The drug is oral-activation-only — snorting, injecting, smoking do not bypass the enzymatic step, so none of those routes produce a faster onset or higher peak (Jasinski & Krishnan 2009²). And food does not meaningfully change absorption, which is unusual for stimulants (Vyvanse FDA label³). The one-sentence summary: Vyvanse is dextroamphetamine with a slow-release mechanism built into the molecule, not the pill.

Mixed salts and the d:l ratio

Adderall is four amphetamine salts at equal weights — dextroamphetamine saccharate, dextroamphetamine sulfate, amphetamine aspartate, amphetamine sulfate. Net composition is roughly 75% dextroamphetamine and 25% levoamphetamine, the often-cited 3:1 ratio (Adderall XR FDA label⁴). The mix has been unchanged since FDA approval for ADHD in 1996.

The levoamphetamine component is the most-cited mechanistic candidate for why Adderall feels different from pure d-amphetamine. L-amphetamine produces weaker dopaminergic effects than the d-isomer but stronger norepinephrine release — more peripheral activation (jaw tightness, jitter), more alerting tone, sometimes more anxiety (Heal et al. 2013⁵). The direct head-to-head pharmacological proof in adult ADHD trials is thin; the subjective profile difference is well-reported clinically.

Two formulations matter. Adderall IR is a single-peak immediate release — peak at ~3 hours, 4–6 hour clinical duration. Adderall XR is a beaded dual-release capsule: half the dose released on ingestion, half delayed by ~4 hours via a polymer-coated bead. The result is two plasma peaks at roughly 3 and 7 hours, 8–10 hour clinical duration. The mid-day dip between peaks is small for most patients but is the structural reason some readers report a 1pm slump on Adderall XR that Vyvanse does not produce.

Duration profiles, side by side

Vyvanse 10–12 hours, slow tail. Adderall XR 8–10 hours, dual peak with steeper drop. Adderall IR 4–6 hours, single peak, sharp drop. Subjective onset: ~30–60 minutes for Adderall IR/XR, ~60–120 minutes for Vyvanse. Sources are the package inserts and Patrick & Markowitz 1997 on amphetamine pharmacokinetics.

The workday shape decides which one fits. A reader whose hardest hours are 8am to 6pm with childcare from 6pm needs the long smooth tail — Vyvanse fits. A reader with a 9am to 2pm focus block and an evening they want unmedicated needs the shorter arc — Adderall XR or even Adderall IR. A reader who needs to feel the medication kick in before they can get started (the “I cannot tell if it is working” problem) does better on Adderall, where the on-signal is part of the design. Vyvanse’s slow on-ramp is its pharmacology, not a defect to titrate around.

Abuse liability — the prodrug protection

The lysine cap means the drug must transit the bloodstream and meet red-cell peptidases before any d-amphetamine is released. Snorting, injecting, smoking — none of these bypass that step. Jasinski & Krishnan 2009² ran the RCT in stimulant-experienced subjects: lisdexamfetamine produced significantly lower Drug-Liking Visual Analog Scale scores than equivalent IR d-amphetamine, especially at supra-therapeutic doses and via intravenous or intranasal routes. The structural protection is at the mechanism level, not the schedule level — both Vyvanse and Adderall remain DEA Schedule II.

Three adult clinical situations where this changes prescriber preference: personal or close-family stimulant misuse history; a supervised medication setting (sober living, monitored professional context); a household where diversion to teenagers, partner, or roommates is a documented concern. The honest framing is that “less abusable” does not mean “non-abusable” — oral lisdexamfetamine at supra-therapeutic doses is still pharmacologically active. The protection is against the rapid-onset, high-peak routes that drive most abuse.

Smoothness vs onset

Patient preference at the class level splits along the pharmacokinetic profile, not the efficacy. Cortese et al. 2018⁶ network meta-analysis pools both as “amphetamines” and shows a large effect on adult outcomes. There is no large adult head-to-head trial directly comparing Vyvanse and Adderall XR at equivalent doses; the comparative claims rest on how the drugs are absorbed and on patient reports.

The Adderall side: noticeable subjective onset in 30–60 minutes, a strong identifiable peak at 2–3 hours, a more abrupt tail, and for some patients a sharper feel — more peripheral activation, more identifiable on/off. The Vyvanse side: slow onset, flatter peak, long smooth tail, sustained focus without the peak-and-trough oscillation. The trade-off cuts both ways: the absent on-signal is a complaint for readers who need to feel the medication land before they can use it.

Dose conversion is not 1:1

FDA-recommended approximate equivalence: 30 mg Vyvanse ≈ 10 mg dextroamphetamine ≈ 20 mg Adderall; 50 mg Vyvanse ≈ 15 mg ≈ 30 mg; 70 mg Vyvanse ≈ 20 mg ≈ 40 mg. The lysine adds ~70% to the molecular weight, which is why the Vyvanse number is bigger for the same d-amphetamine delivered (Vyvanse label³). Inter-individual variation in red-cell peptidase activity and CYP2D6 metabolism means the equivalence is approximate, not exact.

Operational guidance for switching: use the table to identify a target, start one increment below it, re-titrate over 2–4 weeks, and track symptom response on a validated scale (ASRS, AISRS) rather than on subjective feel. The subjective experience will differ even when symptom control is equivalent — the rating scale is what answers whether the new formulation is working.

Cardiovascular profile

Essentially the same. Modest blood-pressure elevation of ~3–5 mmHg and heart-rate increase of ~3–8 bpm at therapeutic doses, both formulations (Stiefel & Besag 2010⁸). Cooper et al. 2011⁷ cohort of more than 150,000 adults in the NEJM found no significant association between current stimulant use and serious cardiovascular events. Monitoring practice is unchanged by formulation — baseline BP/HR, recheck at dose changes and annually, cardiology consult for structural heart disease, uncontrolled hypertension, recent MI, or symptomatic arrhythmia.

Insurance after generic lisdexamfetamine

Generic lisdexamfetamine entered the US market in August 2023 when the Vyvanse patent expired; multiple manufacturers have approved generics as of 2024–2025. The pre-2023 framing — “Vyvanse is brand-only and expensive” — no longer holds by default. Adderall XR generics have been available since 2009; Adderall IR generics longer than that. Current tier shape varies by plan: generic lisdexamfetamine is now tier 1–2 on many commercial plans; brand Vyvanse usually tier 3–4 with prior authorisation.

The 2022–2026 stimulant shortage has affected both Adderall and Vyvanse at different points, so pharmacy availability is sometimes the limiting factor rather than insurance or prescriber preference. In the UK, both lisdexamfetamine (sold as Elvanse) and mixed amphetamine salts are available; NICE NG87⁹ lists lisdexamfetamine as a first-line stimulant option for adults, and UK prescribing tends to favour it on cost-effectiveness grounds.

For readers whose Vyvanse-vs-Adderall question is actually a tachyphylaxis question — same medication, week-three drop in effect — see the medication cliff. For the broader overview, see ADHD medication.